IMPACT OF MELATONIN ON SEDATIVE INFUSION REQUIREMENTS IN COVID-19-ASSOCIATED RESPIRATORY FAILURE

ABSTRACT

Sedative requirements on days following nightly melatonin administration ( I melatonin days i ) were compared to requirements on days following no nightly melatonin administration ( I non-melatonin days i ) using paired-sampled t- test. There was no difference in the dose of hydromorphone infusion (1.00 mg/hr vs 1.48 mg/hr;, p =0.31), average number of daily boluses (2.9 vs 2.2;p = 0.40), or average bolus doses (0.66 mg vs 0.69 mg;p=0.88) infused on melatonin vs non-melatonin days. B Conclusions: b Our data suggest that in mechanically ventilated COVID-19 patients, the administration of melatonin does not affect sedative infusion or bolus dosage requirements for commonly used ICU sedatives. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)